Pyridoxine-Dependent Epilepsy

Mendelian MONDO:0020741 Pathograph 8 Show in embeddings browser Epilepsy Inborn Errors of Metabolism Neurodevelopmental Disorder

Pyridoxine-dependent epilepsy - ALDH7A1 (PDE-ALDH7A1) is an autosomal recessive, treatable metabolic epilepsy caused by deficiency of antiquitin (alpha-aminoadipic semialdehyde dehydrogenase), an enzyme of lysine degradation. Loss of antiquitin causes accumulation of alpha-aminoadipic semialdehyde (alpha-AASA) and its cyclic equilibrium form delta-1-piperideine-6-carboxylate (P6C); P6C chemically inactivates pyridoxal 5'-phosphate (PLP, the active form of vitamin B6), producing a secondary intracellular PLP deficiency. Because PLP is the cofactor for glutamic acid decarboxylase and many other neuronal enzymes, its depletion impairs GABA synthesis and drives neonatal-onset seizures that are resistant to standard antiseizure medication but respond to pharmacologic pyridoxine. Intellectual disability is common despite seizure control, motivating adjunct lysine-lowering therapy.

Ask OpenScientist

Ask a research question about Pyridoxine-Dependent Epilepsy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
8
Pathophys.
8
Phenotypes
3
Gaps
8
Pathograph
1
Genes
4
Medical Actions
1
References
1
Deep Research
🏷

Classifications

Harrison's Part
ENDOCRINOLOGY METABOLISM NEUROLOGIC
ICIMD (Inherited Metabolic Disorders)
lys hyl and trp
🔗

Mappings

MONDO
MONDO:0020741 pyridoxine-dependent epilepsy caused by ALDH7A1 mutant
skos:exactMatch MONDO
MONDO:0020741 is the ALDH7A1-caused pyridoxine-dependent epilepsy concept.
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
PDE-ALDH7A1 is inherited in an autosomal recessive manner; affected individuals carry biallelic pathogenic ALDH7A1 variants. Each sib of an affected proband has a 25% chance of being affected.
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:20301659 SUPPORT Human Clinical
"each sib of an affected individual has at conception a 25% chance of being affected"
GeneReviews documents the autosomal recessive 25% sibling recurrence risk.
?

Discussions and Knowledge Gaps

3
Why do most individuals with pyridoxine-dependent epilepsy have persistent intellectual disability despite good seizure control on pyridoxine, and is the residual impairment caused by ongoing (or prenatal) toxic-metabolite exposure rather than by the seizures themselves?
KNOWLEDGE GAP OPEN gap_pde_neurodevelopment_vs_seizure_dissociation
Attached to
pathophysiology#Neurodevelopmental Impairment pathophysiology#Accumulation of Alpha-AASA and P6C
Pyridoxine reliably controls the seizures, yet about three-quarters of individuals have significant developmental delay or intellectual disability, a striking dissociation between seizure control and cognitive outcome. If the residual impairment is driven by continued accumulation of alpha-AASA and P6C (which pyridoxine does not lower), then adding metabolite-lowering therapy could improve development; if it reflects fixed prenatal injury, it would be largely irreducible. Resolving the driver is central to whether and how aggressively to pursue lysine-lowering treatment.
Proposed experiments
Metabolite burden versus neurodevelopmental outcome
biomarker-outcome correlation experiment Relation: this experiment is of type this experiment type This experiment is of type biomarker-outcome correlation experiment.
exp_pde_metabolite_vs_outcome
In a PDE cohort, relate longitudinal alpha-AASA/P6C levels (on pyridoxine alone versus on added lysine-lowering therapy) to neurodevelopmental trajectory, testing whether lowering metabolites improves cognition.
Readouts
Cognitive trajectory versus metabolite level
pathophysiology#Neurodevelopmental Impairment
neuropsychological assessment Relation: this readout is measured by this assay This readout is measured by neuropsychological assessment.
Direction: POSITIVE
Controls
Pyridoxine-only comparator
Individuals on pyridoxine without metabolite-lowering therapy.
Decision criterion
A metabolite-toxicity driver is supported if lower metabolite levels track with better neurodevelopmental outcome within the cohort.
Would support
pathophysiology#Accumulation of Alpha-AASA and P6C
Show evidence (1 reference)
PMID:26026794 SUPPORT Human Clinical
"75% of individuals with PDE have significant developmental delay and intellectual disability"
Establishes the high residual developmental burden despite seizure control, the observation this gap seeks to explain.
Does adjunct lysine-lowering therapy (dietary lysine restriction plus arginine supplementation added to pyridoxine) improve neurodevelopmental outcome, and which patients benefit most?
EMERGING HYPOTHESIS OPEN gap_pde_triple_therapy_neurodevelopmental_benefit
Attached to
pathophysiology#Accumulation of Alpha-AASA and P6C pathophysiology#Neurodevelopmental Impairment
Because pyridoxine does not reduce the accumulating lysine-pathway metabolites, a combined approach that lowers substrate flux (lysine restriction) and competes lysine transport (arginine) has been proposed to reduce alpha-AASA and P6C and thereby protect the developing brain. Early case series are encouraging but small and uncontrolled, so whether triple therapy meaningfully improves development, and the optimal timing and intensity, remains an open, actively investigated question.
Proposed experiments
Controlled evaluation of triple therapy timing and intensity
controlled treatment-comparison experiment Relation: this experiment is of type this experiment type This experiment is of type controlled treatment-comparison experiment.
exp_pde_triple_therapy_trial
In a prospective, ideally controlled study, compare neurodevelopmental outcomes of pyridoxine alone versus pyridoxine plus lysine restriction and arginine, stratified by age at initiation, to define benefit and the treatment window.
Readouts
Developmental outcome by regimen and timing
pathophysiology#Neurodevelopmental Impairment
neuropsychological assessment Relation: this readout is measured by this assay This readout is measured by neuropsychological assessment.
Direction: POSITIVE
Controls
Pyridoxine-only arm
Standard pyridoxine monotherapy as comparator.
Decision criterion
The hypothesis is supported if adding lysine-lowering therapy improves developmental outcome versus pyridoxine alone, especially with earlier initiation.
Would support
pathophysiology#Neurodevelopmental Impairment
Show evidence (1 reference)
PMID:26026794 SUPPORT Human Clinical
"We describe a new combined therapeutic approach to reduce putative toxic metabolites from impaired lysine metabolism."
Introduces the triple-therapy strategy whose neurodevelopmental benefit is the open hypothesis.
Given the prenatal footprint of the disorder (fetal ventriculomegaly and abnormal fetal movements), is a substantial part of the neurodevelopmental injury incurred before birth, and could prenatal or immediate postnatal metabolite-lowering treatment prevent it?
KNOWLEDGE GAP OPEN gap_pde_prenatal_onset_treatment_window
Attached to
pathophysiology#Neurodevelopmental Impairment
The phenotype can begin in utero, implying that toxic-metabolite exposure and cofactor deficiency may injure the brain before treatment can begin postnatally. If a meaningful fraction of the developmental deficit is prenatal, then the achievable benefit of any postnatal therapy is bounded, and prenatal or immediate-postnatal intervention (in known at-risk pregnancies) becomes the logical target. How much injury is prenatal versus postnatal, and whether early intervention changes outcome, is unresolved.
Proposed experiments
Partitioning prenatal versus postnatal injury
prenatal-versus-postnatal injury partition experiment Relation: this experiment is of type this experiment type This experiment is of type prenatal-versus-postnatal injury partition experiment.
exp_pde_prenatal_injury_partition
Combine fetal/neonatal imaging and metabolite measurement with long-term outcome, and in at-risk pregnancies evaluate early (including prenatal maternal) lysine-lowering strategies, to estimate the prenatal injury fraction and whether early treatment alters outcome.
Readouts
Outcome by injury timing and early treatment
pathophysiology#Neurodevelopmental Impairment
neuropsychological assessment Relation: this readout is measured by this assay This readout is measured by neuropsychological assessment. magnetic resonance imaging assay Relation: this readout is measured by this assay This readout is measured by magnetic resonance imaging assay.
Direction: POSITIVE
Controls
Postnatally-treated comparator
Individuals treated only after birth.
Decision criterion
A substantial prenatal-injury contribution is supported if outcome correlates with prenatal imaging/metabolite burden and is not fully rescued by postnatal treatment.
Would support
pathophysiology#Neurodevelopmental Impairment
Show evidence (1 reference)
PMID:20554659 SUPPORT Human Clinical
"from ventriculomegaly detected on foetal ultrasound, through abnormal foetal movements and a multisystem neonatal disorder, to the onset of seizures and autistic features after the first year of life."
Documents the prenatal-onset end of the spectrum, the basis for asking how much injury precedes any postnatal treatment.
⚙

Pathophysiology

8
Antiquitin (ALDH7A1) Deficiency
Biallelic loss-of-function variants in ALDH7A1 abolish antiquitin (alpha-aminoadipic semialdehyde dehydrogenase) activity, a step in the saccharopine pathway of lysine degradation. This node captures the single concept of the enzyme deficiency.
ALDH7A1 hgnc:877 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves ALDH7A1 (hgnc:877). hgnc:877 is a gene from the HUGO Gene Nomenclature Committee.
saccharopine-pathway lysine degradation GO:0019477 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased saccharopine-pathway lysine degradation, annotated with L-lysine catabolic process (GO:0019477). GO:0019477 is a biological process from the Gene Ontology. ↓ DECREASED
alpha-aminoadipic semialdehyde (antiquitin) dehydrogenase activity GO:0004043 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased alpha-aminoadipic semialdehyde (antiquitin) dehydrogenase activity, annotated with L-aminoadipate-semialdehyde dehydrogenase [NAD(P)+] activity (GO:0004043). GO:0004043 is a molecular function from the Gene Ontology. ↓ DECREASED Aldehyde dehydrogenase (NAD+) activity GO:0004029 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased Aldehyde dehydrogenase (NAD+) activity (GO:0004029). GO:0004029 is a molecular function from the Gene Ontology. ↓ DECREASED
Downstream
Accumulation of Alpha-AASA and P6C Loss of antiquitin blocks the pathway, so its substrate alpha-AASA and the cyclic form P6C accumulate.
Show evidence (1 reference)
PMID:16491085 SUPPORT Human Clinical
"We show here that children with pyridoxine-dependent seizures (PDS) have mutations in the ALDH7A1 gene, which encodes antiquitin"
The founding study established biallelic ALDH7A1 (antiquitin) mutations as the cause of pyridoxine-dependent seizures.
Accumulation of Alpha-AASA and P6C
With antiquitin absent, alpha-aminoadipic semialdehyde (alpha-AASA) and its cyclic equilibrium partner delta-1-piperideine-6-carboxylate (P6C) accumulate in tissues and body fluids, where alpha-AASA serves as the diagnostic biomarker. This node captures the single concept of toxic metabolite accumulation.
Neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
saccharopine-pathway lysine degradation GO:0019477 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased saccharopine-pathway lysine degradation, annotated with L-lysine catabolic process (GO:0019477). GO:0019477 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
P6C-Mediated Inactivation of Pyridoxal 5-Phosphate P6C reacts with and inactivates pyridoxal 5'-phosphate.
P6C-Mediated Inactivation of Pyridoxal 5-Phosphate
P6C undergoes a Knoevenagel condensation with pyridoxal 5'-phosphate (PLP), chemically trapping and inactivating the active cofactor form of vitamin B6. This node captures the single concept of the metabolite-driven cofactor inactivation that links the enzyme block to a vitamin deficiency.
Downstream
Secondary Pyridoxal 5-Phosphate Deficiency Ongoing PLP inactivation depletes the intracellular pool of active vitamin B6.
Secondary Pyridoxal 5-Phosphate Deficiency
Chronic inactivation of PLP produces a secondary, intracellular deficiency of the active vitamin B6 cofactor, which pharmacologic pyridoxine can partially overcome. This node captures the single concept of the acquired cofactor deficiency.
Downstream
Impaired PLP-Dependent GABA Synthesis and Excitation-Inhibition Imbalance PLP deficiency impairs the many PLP-dependent neuronal enzymes, notably glutamic acid decarboxylase.
Impaired PLP-Dependent GABA Synthesis and Excitation-Inhibition Imbalance
Glutamic acid decarboxylase, which synthesizes the inhibitory neurotransmitter GABA from glutamate, requires PLP as its cofactor; PLP deficiency lowers GABA synthesis and shifts cortical circuits toward excitation. This node captures the single concept of the excitation-inhibition imbalance and conforms to the shared epilepsy final common pathway.
GABAergic interneuron CL:0000617 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves GABAergic interneuron, annotated with GABAergic neuron (CL:0000617). CL:0000617 is a cell type from the Cell Ontology.
Downstream
Neuronal Hyperexcitability Reduced inhibitory tone renders neonatal networks hyperexcitable.
Neuronal Hyperexcitability
Networks with reduced GABAergic inhibition become hyperexcitable and hypersynchronous. This node captures the single concept of network hyperexcitability and conforms to the shared epilepsy final common pathway.
Neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Downstream
Pyridoxine-Responsive Neonatal Seizures Hyperexcitable networks generate the neonatal-onset seizures.
Pyridoxine-Responsive Neonatal Seizures
The clinical hallmark is neonatal-onset seizures (including status epilepticus and multiple seizure types) that are refractory to standard antiseizure medication but respond to pharmacologic pyridoxine. This node captures the single concept of the treatable seizure endpoint and conforms to the shared epilepsy final common pathway.
Neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Show evidence (1 reference)
PMID:20301659 SUPPORT Human Clinical
"Targeted therapy requires lifelong pharmacologic supplements of pyridoxine"
GeneReviews documents that the seizures are controlled by lifelong pyridoxine, the defining pyridoxine-dependence.
Neurodevelopmental Impairment
Intellectual disability and developmental impairment are common even when seizures are controlled by pyridoxine, attributed in part to ongoing metabolite toxicity - the rationale for adjunct lysine-lowering therapy. This node captures the single concept of the neurodevelopmental outcome.
Neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Show evidence (1 reference)
PMID:26026794 SUPPORT Human Clinical
"75% of individuals with PDE have significant developmental delay and intellectual disability"
Documents the high rate of developmental delay/intellectual disability that persists despite pyridoxine seizure control, the dissociation that motivates metabolite-lowering therapy.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Pyridoxine-Dependent Epilepsy Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

8
Nervous System 5
Intellectual Disability HP:0001249 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intellectual disability (HP:0001249). HP:0001249 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301659 SUPPORT Human Clinical
"Intellectual disability is common"
GeneReviews documents that intellectual disability is common in PDE.
Hypoplasia of the Corpus Callosum HP:0002079 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypoplasia of the corpus callosum (HP:0002079). HP:0002079 is a phenotype from the Human Phenotype Ontology.
Ventriculomegaly HP:0002119 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ventriculomegaly (HP:0002119). HP:0002119 is a phenotype from the Human Phenotype Ontology.
Autistic Features Autism HP:0000717 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Autism (HP:0000717). HP:0000717 is a phenotype from the Human Phenotype Ontology.
Global Developmental Delay HP:0001263 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Global developmental delay (HP:0001263). HP:0001263 is a phenotype from the Human Phenotype Ontology.
Other 3
Neonatal-Onset Seizures Neonatal seizure HP:0032807 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Neonatal seizure (HP:0032807). HP:0032807 is a phenotype from the Human Phenotype Ontology.
Status Epilepticus HP:0002133 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Status epilepticus (HP:0002133). HP:0002133 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301659 SUPPORT Human Clinical
"recurrent episodes of status epilepticus are typical"
GeneReviews documents recurrent status epilepticus as typical in untreated classic PDE.
Infantile Spasms HP:0012469 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Infantile spasms (HP:0012469). HP:0012469 is a phenotype from the Human Phenotype Ontology.
🧬

Genetic Associations

1
ALDH7A1
Gene: ALDH7A1 hgnc:877 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ALDH7A1 (hgnc:877). hgnc:877 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
💊

Medical Actions

4
Pyridoxine Supplementation
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: pyridoxine CHEBI:16709 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses pyridoxine (CHEBI:16709). CHEBI:16709 is a therapeutic agent from Chemical Entities of Biological Interest.
Lifelong pharmacologic pyridoxine (vitamin B6) is the targeted therapy that controls the otherwise refractory seizures.
Show evidence (1 reference)
PMID:20301659 SUPPORT Human Clinical
"Targeted therapy requires lifelong pharmacologic supplements of pyridoxine"
GeneReviews documents lifelong pyridoxine as the targeted therapy.
Lysine-Restricted Diet
Action: dietary interventionNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is dietary intervention (NCIT:C15447). NCIT:C15447 is a clinical intervention from the NCI Thesaurus. Ontology label: Dietary Intervention NCIT:C15447
A lysine-restricted diet lowers production of the toxic metabolites (alpha-AASA/P6C) and is used as adjunct therapy aiming to improve neurodevelopmental outcome beyond seizure control.
Show evidence (1 reference)
PMID:26026794 SUPPORT Human Clinical
"We describe a new combined therapeutic approach to reduce putative toxic metabolites from impaired lysine metabolism."
Describes the combined (triple) therapy - pyridoxine plus arginine plus dietary lysine restriction - aimed at lowering the toxic lysine-pathway metabolites.
Arginine Supplementation
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: L-arginine CHEBI:16467 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses L-arginine (CHEBI:16467). CHEBI:16467 is a therapeutic agent from Chemical Entities of Biological Interest.
Arginine supplementation competes with lysine for transport and is used as an additional lysine-lowering (metabolite-reducing) adjunct.
Folinic Acid
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Folinic acid has been used as an adjunct; folinic-acid-responsive seizures were historically described as a separate entity but are now known to be allelic to PDE (caused by ALDH7A1 variants).
🔬

Biochemical Markers

1
Elevated Alpha-Aminoadipic Semialdehyde (alpha-AASA) (INCREASED)
Show evidence (1 reference)
PMID:20301659 SUPPORT Human Clinical
"The diagnosis of PDE-ALDH7A1 is suspected in a proband with seizures responsive to pyridoxine administration and increased concentration of alpha-aminoadipic semialdehyde (α-AASA) in urine and/or plasma."
GeneReviews documents elevated alpha-AASA as the biochemical diagnostic marker.
🔬

Diagnosis

1
Alpha-AASA Biomarker and ALDH7A1 Testing
Diagnosis is suspected from pyridoxine-responsive seizures with elevated urine/plasma alpha-AASA and confirmed by biallelic pathogenic ALDH7A1 variants on molecular genetic testing.
Show evidence (1 reference)
PMID:20301659 SUPPORT Human Clinical
"The diagnosis of PDE-ALDH7A1 is suspected in a proband with seizures responsive to pyridoxine administration and increased concentration of alpha-aminoadipic semialdehyde (α-AASA) in urine and/or plasma."
GeneReviews establishes the biomarker-plus-molecular diagnostic pathway.
📊

Prevalence

1
Worldwide (carrier-frequency-based estimate)
Birth Prevalence 1.5 per 100,000 1–9 per 100,000
A rare autosomal recessive inborn error of metabolism. No large direct population survey exists; carrier-frequency modeling from population databases yields an estimated birth incidence on the order of 1 in 60,000 to 1 in 65,000 live births (about 1.5 per 100,000), with clustering in populations carrying founder alleles.
{ }

Source YAML

click to show 
name: Pyridoxine-Dependent Epilepsy
creation_date: "2026-07-18T00:00:00Z"
category: Mendelian
description: >-
  Pyridoxine-dependent epilepsy - ALDH7A1 (PDE-ALDH7A1) is an autosomal
  recessive, treatable metabolic epilepsy caused by deficiency of antiquitin
  (alpha-aminoadipic semialdehyde dehydrogenase), an enzyme of lysine
  degradation. Loss of antiquitin causes accumulation of
  alpha-aminoadipic semialdehyde (alpha-AASA) and its cyclic equilibrium form
  delta-1-piperideine-6-carboxylate (P6C); P6C chemically inactivates
  pyridoxal 5'-phosphate (PLP, the active form of vitamin B6), producing a
  secondary intracellular PLP deficiency. Because PLP is the cofactor for
  glutamic acid decarboxylase and many other neuronal enzymes, its depletion
  impairs GABA synthesis and drives neonatal-onset seizures that are resistant
  to standard antiseizure medication but respond to pharmacologic pyridoxine.
  Intellectual disability is common despite seizure control, motivating adjunct
  lysine-lowering therapy.
parents:
- Epilepsy
- Inborn Errors of Metabolism
- Neurodevelopmental Disorder
synonyms:
- PDE-ALDH7A1
- Antiquitin deficiency
- Alpha-aminoadipic semialdehyde dehydrogenase deficiency
- Pyridoxine-dependent epilepsy caused by ALDH7A1 mutant
disease_term:
  preferred_term: pyridoxine-dependent epilepsy (ALDH7A1)
  term:
    id: MONDO:0020741
    label: pyridoxine-dependent epilepsy caused by ALDH7A1 mutant
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0020741
      label: pyridoxine-dependent epilepsy caused by ALDH7A1 mutant
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO:0020741 is the ALDH7A1-caused pyridoxine-dependent epilepsy concept.
classifications:
  harrisons_chapter:
  - classification_value: ENDOCRINOLOGY_METABOLISM
    notes: >-
      An inborn error of lysine degradation: antiquitin (ALDH7A1) deficiency
      blocks the alpha-aminoadipic semialdehyde dehydrogenase step.
  - classification_value: NEUROLOGIC
    notes: >-
      Clinically a neonatal-onset epilepsy, so the epilepsy/neurology Part is
      the primary clinical home.
  icimd_category:
  - classification_value: lys_hyl_and_trp
    notes: >-
      ICIMD (Ferreira et al. 2021, PMID:33340416): group "Disorders of lysine,
      hydroxylysine and tryptophan metabolism" under category "Disorders of
      amino acid metabolism". The primary enzymatic lesion is in lysine
      degradation; the pyridoxal 5'-phosphate deficiency is a secondary
      consequence of P6C accumulation, so this entry is classified with the
      amino-acid disorders rather than under "Disorders of pyridoxine
      metabolism" (which is where the primary PLP-synthesis defect, PNPO
      deficiency, belongs).
references:
- reference: PMID:20301659
  title: "Pyridoxine-Dependent Epilepsy – ALDH7A1."
  tags:
  - GeneReviews
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    PDE-ALDH7A1 is inherited in an autosomal recessive manner; affected
    individuals carry biallelic pathogenic ALDH7A1 variants. Each sib of an
    affected proband has a 25% chance of being affected.
  evidence:
  - reference: PMID:20301659
    reference_title: "Pyridoxine-Dependent Epilepsy – ALDH7A1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "each sib of an affected individual has at conception a 25% chance of being affected"
    explanation: GeneReviews documents the autosomal recessive 25% sibling recurrence risk.
pathophysiology:
- name: Antiquitin (ALDH7A1) Deficiency
  description: >-
    Biallelic loss-of-function variants in ALDH7A1 abolish antiquitin
    (alpha-aminoadipic semialdehyde dehydrogenase) activity, a step in the
    saccharopine pathway of lysine degradation. This node captures the single
    concept of the enzyme deficiency.
  role: trigger
  gene:
    preferred_term: ALDH7A1
    term:
      id: hgnc:877
      label: ALDH7A1
  molecular_functions:
  - preferred_term: alpha-aminoadipic semialdehyde (antiquitin) dehydrogenase activity
    term:
      id: GO:0004043
      label: L-aminoadipate-semialdehyde dehydrogenase [NAD(P)+] activity
    modifier: DECREASED
  - preferred_term: Aldehyde dehydrogenase (NAD+) activity
    term:
      id: GO:0004029
      label: aldehyde dehydrogenase (NAD+) activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: saccharopine-pathway lysine degradation
    term:
      id: GO:0019477
      label: L-lysine catabolic process
    modifier: DECREASED
  evidence:
  - reference: PMID:16491085
    reference_title: "Mutations in antiquitin in individuals with pyridoxine-dependent seizures."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We show here that children with pyridoxine-dependent seizures (PDS) have mutations in the ALDH7A1 gene, which encodes antiquitin"
    explanation: >-
      The founding study established biallelic ALDH7A1 (antiquitin) mutations as
      the cause of pyridoxine-dependent seizures.
  downstream:
  - target: Accumulation of Alpha-AASA and P6C
    causal_link_type: DIRECT
    description: >-
      Loss of antiquitin blocks the pathway, so its substrate alpha-AASA and the
      cyclic form P6C accumulate.
    evidence:
    - reference: PMID:26026794
      reference_title: "Triple therapy with pyridoxine, arginine supplementation and dietary lysine restriction in pyridoxine-dependent epilepsy: Neurodevelopmental outcome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "PDE is caused by deficiency of α-aminoadipic semialdehyde dehydrogenase resulting in impaired lysine degradation and subsequent accumulation of α-aminoadipic semialdehyde"
      explanation: >-
        States the causal step directly: loss of the antiquitin
        (alpha-aminoadipic semialdehyde dehydrogenase) activity blocks lysine
        degradation and causes the substrate to accumulate.
- name: Accumulation of Alpha-AASA and P6C
  description: >-
    With antiquitin absent, alpha-aminoadipic semialdehyde (alpha-AASA) and its
    cyclic equilibrium partner delta-1-piperideine-6-carboxylate (P6C)
    accumulate in tissues and body fluids, where alpha-AASA serves as the
    diagnostic biomarker. This node captures the single concept of toxic
    metabolite accumulation.
  role: mediator
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: saccharopine-pathway lysine degradation
    term:
      id: GO:0019477
      label: L-lysine catabolic process
    modifier: DECREASED
  downstream:
  - target: P6C-Mediated Inactivation of Pyridoxal 5-Phosphate
    causal_link_type: DIRECT
    description: >-
      P6C reacts with and inactivates pyridoxal 5'-phosphate.
    evidence:
    - reference: PMID:16491085
      reference_title: "Mutations in antiquitin in individuals with pyridoxine-dependent seizures."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The accumulating P6C inactivates pyridoxal 5'-phosphate (PLP) by forming a Knoevenagel condensation product."
      explanation: >-
        Identifies the accumulating metabolite P6C as the species that
        chemically inactivates PLP, which is the causal link this edge asserts.
- name: P6C-Mediated Inactivation of Pyridoxal 5-Phosphate
  description: >-
    P6C undergoes a Knoevenagel condensation with pyridoxal 5'-phosphate (PLP),
    chemically trapping and inactivating the active cofactor form of vitamin B6.
    This node captures the single concept of the metabolite-driven cofactor
    inactivation that links the enzyme block to a vitamin deficiency.
  role: mediator
  downstream:
  - target: Secondary Pyridoxal 5-Phosphate Deficiency
    causal_link_type: DIRECT
    description: >-
      Ongoing PLP inactivation depletes the intracellular pool of active
      vitamin B6.
    evidence:
    - reference: PMID:30671974
      reference_title: "Disorders affecting vitamin B(6) metabolism."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "disorders where metabolites accumulate that inactivate PLP, for example, ALDH7A1 deficiency and hyperprolinaemia type II"
      explanation: >-
        This review classifies ALDH7A1 deficiency specifically as a disorder in
        which accumulating metabolites inactivate PLP and thereby produce PLP
        deficiency. Evidence source is OTHER because this is a review article.
- name: Secondary Pyridoxal 5-Phosphate Deficiency
  description: >-
    Chronic inactivation of PLP produces a secondary, intracellular deficiency
    of the active vitamin B6 cofactor, which pharmacologic pyridoxine can
    partially overcome. This node captures the single concept of the acquired
    cofactor deficiency.
  role: mediator
  downstream:
  - target: Impaired PLP-Dependent GABA Synthesis and Excitation-Inhibition Imbalance
    causal_link_type: DIRECT
    description: >-
      PLP deficiency impairs the many PLP-dependent neuronal enzymes, notably
      glutamic acid decarboxylase.
    evidence:
    - reference: PMID:30671974
      reference_title: "Disorders affecting vitamin B(6) metabolism."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Because of the vital role of PLP in neurotransmitter metabolism, particularly synthesis of the inhibitory transmitter γ-aminobutyric acid"
      explanation: >-
        Ties PLP availability to synthesis of the inhibitory transmitter GABA,
        the PLP-dependent step this edge claims is impaired. Evidence source is
        OTHER because this is a review article.
- name: Impaired PLP-Dependent GABA Synthesis and Excitation-Inhibition Imbalance
  description: >-
    Glutamic acid decarboxylase, which synthesizes the inhibitory
    neurotransmitter GABA from glutamate, requires PLP as its cofactor; PLP
    deficiency lowers GABA synthesis and shifts cortical circuits toward
    excitation. This node captures the single concept of the
    excitation-inhibition imbalance and conforms to the shared epilepsy final
    common pathway.
  role: mediator
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance"
  cell_types:
  - preferred_term: GABAergic interneuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  downstream:
  - target: Neuronal Hyperexcitability
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Reduced inhibitory tone renders neonatal networks hyperexcitable.
    evidence:
    - reference: PMID:30764523
      reference_title: "Pediatric Epilepsy Mechanisms: Expanding the Paradigm of Excitation/Inhibition Imbalance."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "increased excitation, decreased inhibition, or both favor a hyperexcitable state"
      explanation: >-
        States the general mechanism this edge specializes: loss of inhibitory
        tone produces a hyperexcitable network state. Evidence source is OTHER
        because this is a review article, and the link is annotated
        INDIRECT_KNOWN_INTERMEDIATES accordingly.
- name: Neuronal Hyperexcitability
  description: >-
    Networks with reduced GABAergic inhibition become hyperexcitable and
    hypersynchronous. This node captures the single concept of network
    hyperexcitability and conforms to the shared epilepsy final common pathway.
  role: central_effector
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Neuronal Hyperexcitability and Hypersynchrony"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Pyridoxine-Responsive Neonatal Seizures
    causal_link_type: DIRECT
    description: >-
      Hyperexcitable networks generate the neonatal-onset seizures.
    evidence:
    - reference: PMID:30764523
      reference_title: "Pediatric Epilepsy Mechanisms: Expanding the Paradigm of Excitation/Inhibition Imbalance."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "a hyperexcitable state and an increased propensity for seizure generation and epileptogenesis"
      explanation: >-
        Connects the hyperexcitable network state to seizure generation, the
        step this edge asserts. Evidence source is OTHER because this is a
        review article.
- name: Pyridoxine-Responsive Neonatal Seizures
  description: >-
    The clinical hallmark is neonatal-onset seizures (including status
    epilepticus and multiple seizure types) that are refractory to standard
    antiseizure medication but respond to pharmacologic pyridoxine. This node
    captures the single concept of the treatable seizure endpoint and conforms
    to the shared epilepsy final common pathway.
  role: consequence
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:20301659
    reference_title: "Pyridoxine-Dependent Epilepsy – ALDH7A1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Targeted therapy requires lifelong pharmacologic supplements of pyridoxine"
    explanation: >-
      GeneReviews documents that the seizures are controlled by lifelong
      pyridoxine, the defining pyridoxine-dependence.
- name: Neurodevelopmental Impairment
  description: >-
    Intellectual disability and developmental impairment are common even when
    seizures are controlled by pyridoxine, attributed in part to ongoing
    metabolite toxicity - the rationale for adjunct lysine-lowering therapy.
    This node captures the single concept of the neurodevelopmental outcome.
  role: effector
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:26026794
    reference_title: "Triple therapy with pyridoxine, arginine supplementation and dietary lysine restriction in pyridoxine-dependent epilepsy: Neurodevelopmental outcome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "75% of individuals with PDE have significant developmental delay and intellectual disability"
    explanation: >-
      Documents the high rate of developmental delay/intellectual disability
      that persists despite pyridoxine seizure control, the dissociation that
      motivates metabolite-lowering therapy.
phenotypes:
- name: Neonatal-Onset Seizures
  description: >-
    Seizures begin in the neonatal period (or, in atypical cases, later
    infancy), are refractory to standard antiseizure medication, and respond to
    pyridoxine.
  phenotype_term:
    preferred_term: Neonatal seizure
    term:
      id: HP:0032807
      label: Neonatal seizure
- name: Status Epilepticus
  description: Prolonged seizures and recurrent status epilepticus are typical when untreated.
  phenotype_term:
    preferred_term: Status epilepticus
    term:
      id: HP:0002133
      label: Status epilepticus
  evidence:
  - reference: PMID:20301659
    reference_title: "Pyridoxine-Dependent Epilepsy – ALDH7A1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "recurrent episodes of status epilepticus are typical"
    explanation: GeneReviews documents recurrent status epilepticus as typical in untreated classic PDE.
- name: Infantile Spasms
  description: Infantile spasms are among the seizure types that can occur.
  phenotype_term:
    preferred_term: Infantile spasms
    term:
      id: HP:0012469
      label: Infantile spasms
- name: Intellectual Disability
  description: Intellectual disability is common, particularly in classic PDE-ALDH7A1.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:20301659
    reference_title: "Pyridoxine-Dependent Epilepsy – ALDH7A1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Intellectual disability is common"
    explanation: GeneReviews documents that intellectual disability is common in PDE.
- name: Hypoplasia of the Corpus Callosum
  description: >-
    Structural brain abnormalities, particularly corpus callosum hypoplasia, are
    frequently seen on neuroimaging.
  phenotype_term:
    preferred_term: Hypoplasia of the corpus callosum
    term:
      id: HP:0002079
      label: Hypoplasia of the corpus callosum
- name: Ventriculomegaly
  description: >-
    Ventriculomegaly is a frequent structural finding, sometimes detectable
    prenatally on fetal ultrasound.
  phenotype_term:
    preferred_term: Ventriculomegaly
    term:
      id: HP:0002119
      label: Ventriculomegaly
- name: Autistic Features
  description: Autistic features occur in a subset of individuals.
  phenotype_term:
    preferred_term: Autism
    term:
      id: HP:0000717
      label: Autism
- name: Global Developmental Delay
  description: Developmental delay is frequent despite seizure control.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
biochemical:
- name: Elevated Alpha-Aminoadipic Semialdehyde (alpha-AASA)
  biomarker_term:
    preferred_term: alpha-aminoadipic semialdehyde
    term:
      id: CHEBI:17917
      label: L-allysine
  presence: INCREASED
  notes: >-
    Increased alpha-aminoadipic semialdehyde (alpha-AASA) in urine and/or plasma
    is the diagnostic biomarker, reflecting the antiquitin block.
  evidence:
  - reference: PMID:20301659
    reference_title: "Pyridoxine-Dependent Epilepsy – ALDH7A1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of PDE-ALDH7A1 is suspected in a proband with seizures responsive to pyridoxine administration and increased concentration of alpha-aminoadipic semialdehyde (α-AASA) in urine and/or plasma."
    explanation: >-
      GeneReviews documents elevated alpha-AASA as the biochemical diagnostic
      marker.
genetic:
- name: ALDH7A1
  gene_term:
    preferred_term: ALDH7A1
    term:
      id: hgnc:877
      label: ALDH7A1
  relationship_type: CAUSATIVE
  notes: >-
    ALDH7A1 (5q23.2) encodes antiquitin (alpha-aminoadipic semialdehyde
    dehydrogenase). Biallelic pathogenic variants cause PDE-ALDH7A1; the common
    recurrent variant is c.1279G>C (p.Glu427Gln) in many populations.
diagnosis:
- name: Alpha-AASA Biomarker and ALDH7A1 Testing
  description: >-
    Diagnosis is suspected from pyridoxine-responsive seizures with elevated
    urine/plasma alpha-AASA and confirmed by biallelic pathogenic ALDH7A1
    variants on molecular genetic testing.
  evidence:
  - reference: PMID:20301659
    reference_title: "Pyridoxine-Dependent Epilepsy – ALDH7A1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of PDE-ALDH7A1 is suspected in a proband with seizures responsive to pyridoxine administration and increased concentration of alpha-aminoadipic semialdehyde (α-AASA) in urine and/or plasma."
    explanation: >-
      GeneReviews establishes the biomarker-plus-molecular diagnostic pathway.
treatments:
- name: Pyridoxine Supplementation
  description: >-
    Lifelong pharmacologic pyridoxine (vitamin B6) is the targeted therapy that
    controls the otherwise refractory seizures.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: pyridoxine
      term:
        id: CHEBI:16709
        label: pyridoxine
  evidence:
  - reference: PMID:20301659
    reference_title: "Pyridoxine-Dependent Epilepsy – ALDH7A1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Targeted therapy requires lifelong pharmacologic supplements of pyridoxine"
    explanation: >-
      GeneReviews documents lifelong pyridoxine as the targeted therapy.
- name: Lysine-Restricted Diet
  description: >-
    A lysine-restricted diet lowers production of the toxic metabolites
    (alpha-AASA/P6C) and is used as adjunct therapy aiming to improve
    neurodevelopmental outcome beyond seizure control.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: NCIT:C15447
      label: Dietary Intervention
  evidence:
  - reference: PMID:26026794
    reference_title: "Triple therapy with pyridoxine, arginine supplementation and dietary lysine restriction in pyridoxine-dependent epilepsy: Neurodevelopmental outcome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We describe a new combined therapeutic approach to reduce putative toxic metabolites from impaired lysine metabolism."
    explanation: >-
      Describes the combined (triple) therapy - pyridoxine plus arginine plus
      dietary lysine restriction - aimed at lowering the toxic lysine-pathway
      metabolites.
- name: Arginine Supplementation
  description: >-
    Arginine supplementation competes with lysine for transport and is used as
    an additional lysine-lowering (metabolite-reducing) adjunct.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: L-arginine
      term:
        id: CHEBI:16467
        label: L-arginine
- name: Folinic Acid
  description: >-
    Folinic acid has been used as an adjunct; folinic-acid-responsive seizures
    were historically described as a separate entity but are now known to be
    allelic to PDE (caused by ALDH7A1 variants).
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
prevalence:
- population: Worldwide (carrier-frequency-based estimate)
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 1.5
  notes: >-
    A rare autosomal recessive inborn error of metabolism. No large direct
    population survey exists; carrier-frequency modeling from population
    databases yields an estimated birth incidence on the order of 1 in 60,000 to
    1 in 65,000 live births (about 1.5 per 100,000), with clustering in
    populations carrying founder alleles.
datasets: []
discussions:
- discussion_id: gap_pde_neurodevelopment_vs_seizure_dissociation
  prompt: >-
    Why do most individuals with pyridoxine-dependent epilepsy have persistent
    intellectual disability despite good seizure control on pyridoxine, and is
    the residual impairment caused by ongoing (or prenatal) toxic-metabolite
    exposure rather than by the seizures themselves?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Neurodevelopmental Impairment
  - pathophysiology#Accumulation of Alpha-AASA and P6C
  rationale: >-
    Pyridoxine reliably controls the seizures, yet about three-quarters of
    individuals have significant developmental delay or intellectual disability,
    a striking dissociation between seizure control and cognitive outcome. If the
    residual impairment is driven by continued accumulation of alpha-AASA and
    P6C (which pyridoxine does not lower), then adding metabolite-lowering
    therapy could improve development; if it reflects fixed prenatal injury, it
    would be largely irreducible. Resolving the driver is central to whether and
    how aggressively to pursue lysine-lowering treatment.
  evidence:
  - reference: PMID:26026794
    reference_title: "Triple therapy with pyridoxine, arginine supplementation and dietary lysine restriction in pyridoxine-dependent epilepsy: Neurodevelopmental outcome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "75% of individuals with PDE have significant developmental delay and intellectual disability"
    explanation: >-
      Establishes the high residual developmental burden despite seizure control,
      the observation this gap seeks to explain.
  proposed_experiments:
  - experiment_id: exp_pde_metabolite_vs_outcome
    name: Metabolite burden versus neurodevelopmental outcome
    description: >-
      In a PDE cohort, relate longitudinal alpha-AASA/P6C levels (on pyridoxine
      alone versus on added lysine-lowering therapy) to neurodevelopmental
      trajectory, testing whether lowering metabolites improves cognition.
    experiment_type:
      preferred_term: biomarker-outcome correlation experiment
    readouts:
    - name: Cognitive trajectory versus metabolite level
      target: pathophysiology#Neurodevelopmental Impairment
      assays:
      - preferred_term: neuropsychological assessment
      direction: POSITIVE
    controls:
    - name: Pyridoxine-only comparator
      description: Individuals on pyridoxine without metabolite-lowering therapy.
    decision_criterion: >-
      A metabolite-toxicity driver is supported if lower metabolite levels track
      with better neurodevelopmental outcome within the cohort.
    would_support:
    - pathophysiology#Accumulation of Alpha-AASA and P6C

- discussion_id: gap_pde_triple_therapy_neurodevelopmental_benefit
  prompt: >-
    Does adjunct lysine-lowering therapy (dietary lysine restriction plus
    arginine supplementation added to pyridoxine) improve neurodevelopmental
    outcome, and which patients benefit most?
  kind: EMERGING_HYPOTHESIS
  status: OPEN
  attaches_to:
  - pathophysiology#Accumulation of Alpha-AASA and P6C
  - pathophysiology#Neurodevelopmental Impairment
  rationale: >-
    Because pyridoxine does not reduce the accumulating lysine-pathway
    metabolites, a combined approach that lowers substrate flux (lysine
    restriction) and competes lysine transport (arginine) has been proposed to
    reduce alpha-AASA and P6C and thereby protect the developing brain. Early
    case series are encouraging but small and uncontrolled, so whether triple
    therapy meaningfully improves development, and the optimal timing and
    intensity, remains an open, actively investigated question.
  evidence:
  - reference: PMID:26026794
    reference_title: "Triple therapy with pyridoxine, arginine supplementation and dietary lysine restriction in pyridoxine-dependent epilepsy: Neurodevelopmental outcome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We describe a new combined therapeutic approach to reduce putative toxic metabolites from impaired lysine metabolism."
    explanation: >-
      Introduces the triple-therapy strategy whose neurodevelopmental benefit is
      the open hypothesis.
  proposed_experiments:
  - experiment_id: exp_pde_triple_therapy_trial
    name: Controlled evaluation of triple therapy timing and intensity
    description: >-
      In a prospective, ideally controlled study, compare neurodevelopmental
      outcomes of pyridoxine alone versus pyridoxine plus lysine restriction and
      arginine, stratified by age at initiation, to define benefit and the
      treatment window.
    experiment_type:
      preferred_term: controlled treatment-comparison experiment
    readouts:
    - name: Developmental outcome by regimen and timing
      target: pathophysiology#Neurodevelopmental Impairment
      assays:
      - preferred_term: neuropsychological assessment
      direction: POSITIVE
    controls:
    - name: Pyridoxine-only arm
      description: Standard pyridoxine monotherapy as comparator.
    decision_criterion: >-
      The hypothesis is supported if adding lysine-lowering therapy improves
      developmental outcome versus pyridoxine alone, especially with earlier
      initiation.
    would_support:
    - pathophysiology#Neurodevelopmental Impairment

- discussion_id: gap_pde_prenatal_onset_treatment_window
  prompt: >-
    Given the prenatal footprint of the disorder (fetal ventriculomegaly and
    abnormal fetal movements), is a substantial part of the neurodevelopmental
    injury incurred before birth, and could prenatal or immediate postnatal
    metabolite-lowering treatment prevent it?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Neurodevelopmental Impairment
  rationale: >-
    The phenotype can begin in utero, implying that toxic-metabolite exposure and
    cofactor deficiency may injure the brain before treatment can begin
    postnatally. If a meaningful fraction of the developmental deficit is
    prenatal, then the achievable benefit of any postnatal therapy is bounded,
    and prenatal or immediate-postnatal intervention (in known at-risk
    pregnancies) becomes the logical target. How much injury is prenatal versus
    postnatal, and whether early intervention changes outcome, is unresolved.
  evidence:
  - reference: PMID:20554659
    reference_title: "Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "from ventriculomegaly detected on foetal ultrasound, through abnormal foetal movements and a multisystem neonatal disorder, to the onset of seizures and autistic features after the first year of life."
    explanation: >-
      Documents the prenatal-onset end of the spectrum, the basis for asking how
      much injury precedes any postnatal treatment.
  proposed_experiments:
  - experiment_id: exp_pde_prenatal_injury_partition
    name: Partitioning prenatal versus postnatal injury
    description: >-
      Combine fetal/neonatal imaging and metabolite measurement with long-term
      outcome, and in at-risk pregnancies evaluate early (including prenatal
      maternal) lysine-lowering strategies, to estimate the prenatal injury
      fraction and whether early treatment alters outcome.
    experiment_type:
      preferred_term: prenatal-versus-postnatal injury partition experiment
    readouts:
    - name: Outcome by injury timing and early treatment
      target: pathophysiology#Neurodevelopmental Impairment
      assays:
      - preferred_term: neuropsychological assessment
      - preferred_term: magnetic resonance imaging assay
      direction: POSITIVE
    controls:
    - name: Postnatally-treated comparator
      description: Individuals treated only after birth.
    decision_criterion: >-
      A substantial prenatal-injury contribution is supported if outcome
      correlates with prenatal imaging/metabolite burden and is not fully
      rescued by postnatal treatment.
    would_support:
    - pathophysiology#Neurodevelopmental Impairment
📚

References & Deep Research

References

1
PMID:20301659
Pyridoxine-Dependent Epilepsy – ALDH7A1.
No top-level findings curated for this source.

Deep Research

1
Claude Code ▸
1. Disease Information
claude-haiku-4-5-20251001, claude-opus-4-8 21 citations 2026-07-18T08:46:14.840059

1. Disease Information

Pyridoxine-dependent epilepsy (PDE), in its classic form, is an autosomal recessive neurometabolic epileptic encephalopathy caused by biallelic loss-of-function variants in ALDH7A1, the gene encoding α-aminoadipic semialdehyde dehydrogenase (α-AASA dehydrogenase), better known as antiquitin (ATQ). The defining clinical signature is early-onset, drug-refractory seizures that stop — clinically and electrographically — in response to large daily doses of pyridoxine (vitamin B6), and that recur if pyridoxine is withdrawn.

The current NCBI GeneReviews framing: "Pyridoxine-dependent epilepsy – ALDH7A1 (PDE-ALDH7A1) is characterized by seizures not well controlled with anti-seizure medication that are responsive clinically and electrographically to large daily supplements of pyridoxine (vitamin B6)" (GeneReviews, NBK1486).

Key identifiers:

Resource Identifier
MONDO MONDO:0009945 (pyridoxine-dependent epilepsy) — confirm against local sqlite:obo:mondo before use
OMIM (disease) #266100 — "EPILEPSY, EARLY-ONSET, 4, VITAMIN B6-DEPENDENT; EPEO4" (the entry was renamed from "pyridoxine-dependent epilepsy")
OMIM (gene) *107323 — ALDH7A1
Orphanet ORPHA:3006 (Pyridoxine-dependent epilepsy) — verify code
HGNC hgnc:877 — ALDH7A1 (lowercase prefix per repo convention; verify number)
ICD-10 G40.4 (other generalized epilepsy) — nonspecific; PDE has no dedicated code
ICD-11 8A61 / 5C60.A range (inborn error of B6 metabolism) — approximate
MeSH "Epilepsy" + "Pyridoxine" (no dedicated PDE MeSH; often indexed as "Seizures/metabolism")

Synonyms / alternative names: antiquitin deficiency; α-AASA dehydrogenase deficiency; pyridoxine-dependent seizures (PDS, older term); vitamin B6-dependent epilepsy (ALDH7A1 type); EPEO4. Note that "folinic acid-responsive seizures" (FARS) is now known to be the same disorder — allelic to PDE, caused by ALDH7A1 variants (Gallagher et al., 2009 [VERIFY PMID: 19128019]).

Data provenance: the knowledge here is drawn almost entirely from aggregated disease-level resources (OMIM, Orphanet, GeneReviews) and published cohort/case-series literature — not EHR-level individual patient records. The largest structured cohorts are the international PDE registry work behind Mills et al. 2010 and the consensus recommendations of the international PDE consortium.

Sources: GeneReviews NBK1486, OMIM #266100, MedlinePlus Genetics.

2. Etiology

Primary cause — genetic: biallelic (homozygous or compound heterozygous) pathogenic variants in ALDH7A1 (chromosome 5q23.2). This is a monogenic inborn error of lysine catabolism; there is no meaningful infectious or acquired etiology for classic PDE.

Causal chain in one breath: loss of antiquitin → block in the saccharopine/lysine-degradation pathway → build-up of Δ¹-piperideine-6-carboxylate (P6C) → P6C chemically inactivates pyridoxal 5′-phosphate (PLP, the active B6 cofactor) → functional B6 deficiency in the brain → seizures.

Genetic risk factors: - Causal variants: >165 published pathogenic ALDH7A1 variants (see §4). The single most common is c.1279G>C (p.Glu427Gln, historically "E399Q"), present in ~30% of European patient alleles. - Consanguinity raises risk (as for any AR disorder) and is over-represented in some reported cohorts. - Founder effects: a Dutch founder haplotype underlies the E399Q allele in several apparently unrelated Dutch families (Bennett/Salomons et al., 2007, "An intriguing 'silent' mutation and a founder effect in antiquitin (ALDH7A1)", PMID:17721876).

Environmental risk / protective / gene-environment factors: essentially none in the conventional sense — penetrance is complete and disease expression does not depend on exposures. The one true gene-environment interaction is therapeutic: dietary lysine load worsens metabolite accumulation (more substrate → more toxic product), while dietary lysine restriction and L-arginine supplementation reduce it (arginine competes with lysine for transport into brain and mitochondria). So "diet" behaves as a modifiable environmental lever on a fixed genetic defect rather than a cause. No protective genetic alleles are described.

Sources: Mills 2006, Nat Med, Bennett/Salomons 2007, Coughlin 2015.

3. Phenotypes

PDE is more than epilepsy — it's an encephalopathy with a developmental footprint. The phenotype spans a remarkable range, captured perfectly by Mills et al. 2010:

"...from ventriculomegaly detected on foetal ultrasound, through abnormal foetal movements and a multisystem neonatal disorder, to the onset of seizures and autistic features after the first year of life." [VERBATIM-VERIFIED, PMID:20554659]

Core phenotypes with suggested HPO terms:

Phenotype Type Onset / course Frequency Suggested HPO (verify)
Recurrent/refractory seizures Clinical sign Neonatal (classic) → up to ~3 yr (late-onset) ~Universal HP:0001250 Seizure
Status epilepticus Clinical sign Neonatal Common/typical HP:0002133 Status epilepticus
Neonatal-onset seizures Clinical sign First days–weeks Majority (classic) HP:0032807 / HP:0003623 (neonatal onset)
Myoclonic / atonic / focal / generalized seizures + infantile spasms Clinical sign Infancy Variable mix HP:0001336 Myoclonus; HP:0011097 Epileptic spasms
Intellectual disability / developmental delay Behavioral/cognitive Persistent ~75% even with seizure control HP:0001249 Intellectual disability; HP:0001263 Global developmental delay
Autistic features Behavioral After yr 1 in some Subset HP:0000717 Autism
Thin/hypoplastic posterior corpus callosum (isthmus) Imaging/structural Congenital Near-universal on MRI HP:0002079 Hypoplasia of the corpus callosum
Ventriculomegaly / mega cisterna magna Imaging Fetal/neonatal Frequent HP:0002119 Ventriculomegaly
Encephalopathy / irritability / poor feeding / respiratory distress (neonatal multisystem picture) Clinical Neonatal Subset HP:0001298 Encephalopathy
Electrolyte disturbance (hypoglycemia, hyponatremia, metabolic acidosis) mimicking sepsis Lab abnormality Neonatal Subset —

Severity/progression: seizures are severe and drug-refractory until B6 is given, then dramatically responsive. Neurodevelopmental outcome, however, is frequently impaired independent of seizure control — the striking, clinically important dissociation. Coughlin 2015 states it plainly:

"75% of individuals with PDE have significant developmental delay and intellectual disability" [VERBATIM-VERIFIED, PMID:26026794]

Late-onset/atypical presentations tend to have more favorable cognition, attributed partly to the absence of neonatal seizure-induced injury.

Quality-of-life impact: driven mainly by the intellectual/developmental disability rather than by seizures once controlled — implies lifelong caregiver support, special education, and communication/motor limitations. Formal EQ-5D/PROMIS data specific to PDE are sparse; QoL is inferred from developmental-outcome cohorts.

Sources: Mills 2010, Brain, GeneReviews NBK1486, Coughlin 2023 review, PMC12360241.

4. Genetic / Molecular Information

Causal gene: ALDH7A1 (aldehyde dehydrogenase 7 family member A1), OMIM *107323, chromosome 5q23.2. Encodes antiquitin, an NAD⁺-dependent dehydrogenase.

Enzyme function (verbatim):

"the nicotinamide adenine dinucleotide-dependent dehydrogenation of l-alpha-aminoadipic semialdehyde/L-Delta1-piperideine 6-carboxylate." [VERBATIM-VERIFIED, PMID:20554659]

Variant landscape: - >165 pathogenic variants published across the gene (missense, nonsense, frameshift, splice-site, and larger deletions). - Most common variant: c.1279G>C (p.Glu427Gln; legacy nomenclature p.Glu399Gln / "E399Q") — ClinVar RCV000019610; dbSNP rs121912707. Reported in ~30% of European PDE alleles. (Note the two coordinate systems: the transcript-based p.Glu427Gln and the historical mature-protein-based E399Q refer to the same variant — a common source of chart confusion.) - Founder effect: the E399Q allele carries a Dutch founder haplotype (PMID:17721876). - Variant classification follows ACMG/AMP; most recurrent alleles are Pathogenic/Likely Pathogenic in ClinVar. - Functional consequence: loss of function (abolished α-AASA/P6C dehydrogenase activity). Not gain-of-function, not dominant-negative — carriers are asymptomatic. - Origin: germline (constitutional). Somatic variation is not relevant. - Allele frequency: individual pathogenic alleles are rare in gnomAD; carrier-frequency modeling gives a disease incidence estimate of ~1:64,352 live births (see §9).

Modifier genes: none robustly established. Residual antiquitin activity of specific missense alleles correlates loosely with age of onset/severity, so genotype itself is the main modifier of expressivity.

Epigenetics / chromosomal abnormalities: no disease-specific methylation signature or recurrent large chromosomal rearrangement is characteristic; PDE is a classic single-gene point-mutation/small-indel disorder. Rare whole-gene or multi-exon deletions occur and can be missed by sequencing alone (argues for deletion/duplication analysis when only one variant is found).

Suggested annotations: gene → hgnc:877 (ALDH7A1, verify); GO molecular function GO:0004029 (aldehyde dehydrogenase (NAD+) activity) and GO:0047718 / lysine-catabolism-specific activity; GO:0030170 pyridoxal phosphate binding (for the downstream affected enzymes).

Sources: Mills 2006, Coughlin 2019 genotypic spectrum, PMC6345606, ClinVar RCV000019610, SNPedia rs121912707.

5. Environmental Information

Classic PDE is not driven by environmental, lifestyle, or infectious factors — it's a pure inborn error. The relevant "environmental" dimensions are entirely dietary/therapeutic and secondary:

  • Dietary lysine intake modulates substrate flux into the blocked pathway (higher lysine → more α-AASA/P6C).
  • Catabolic stress (fasting, febrile illness) can precipitate breakthrough seizures in some patients, an important management caveat.
  • No toxin, radiation, occupational exposure, or pathogen is implicated. Infectious workup matters only because the neonatal presentation mimics sepsis/meningitis and delays diagnosis.

Sources: Coughlin 2015, GeneReviews NBK1486.

6. Mechanism / Pathophysiology

This is the heart of the entry — the causal chain from broken enzyme to seizure. Here's the cascade, upstream → downstream:

Step 1 — Enzyme block (upstream trigger). Antiquitin normally converts α-aminoadipic semialdehyde (α-AASA) to α-aminoadipate in the saccharopine pathway of lysine degradation (the brain's main route for breaking down lysine). Loss of antiquitin stalls this step. Cellular compartment: the reaction and its collapse center on cytosolic/mitochondrial lysine catabolism.

Step 2 — Metabolite accumulation. α-AASA piles up and sits in a spontaneous chemical equilibrium with its cyclic Schiff-base form, Δ¹-piperideine-6-carboxylate (P6C). Pipecolic acid also rises (parallel lysine-degradation branch).

Step 3 — The chemical sabotage (the crux). P6C reacts with pyridoxal 5′-phosphate (PLP) — the active form of vitamin B6 — via a Knoevenagel condensation, forming an inactive adduct. Straight from the founding paper:

P6C "inactivates pyridoxal 5'-phosphate (PLP) by forming a Knoevenagel condensation product." [VERBATIM-VERIFIED, PMID:16491085]

This is a chemical trap, not an enzyme-cofactor competition — the P6C literally consumes and neutralizes PLP.

Step 4 — Functional B6 (PLP) deficiency. PLP is the cofactor for ~140 enzymes. The seizure-critical casualty is glutamic acid decarboxylase (GAD), the PLP-dependent enzyme that makes GABA (the brain's principal inhibitory neurotransmitter). PLP depletion → less GABA synthesis.

Step 5 — Excitation/inhibition imbalance → seizures (downstream clinical output). Falling GABAergic inhibition (with likely secondary glutamate/neurotransmitter dysregulation, since PLP also serves aromatic amino acid decarboxylase and others) produces neuronal hyperexcitability and hypersynchrony → refractory seizures. This is why the disease is a downstream conformer of the generic epilepsy_excitation_inhibition_imbalance module (#Excitation-Inhibition Imbalance is the natural conforms_to target).

Step 6 — Independent neurotoxicity (the reason B6 alone isn't enough). Accumulated α-AASA/P6C (and possibly the metabolite 6-oxo-pipecolic acid) are thought to be directly neurotoxic and neurodevelopmentally damaging, which explains the ~75% intellectual-disability rate despite seizure control — and the entire rationale for substrate-reduction (triple) therapy.

Cell types & structures: GABAergic neurons (CL:0000617 GABAergic neuron), broadly cortical/subcortical neurons; the corpus callosum (isthmus) is structurally hypoplastic.

Suggested GO / CHEBI terms: - GO biological process: GO:0019477 L-lysine catabolic process; GO:0009448 GABA metabolic process; GO:0042816 vitamin B6 metabolic process; GO:0006536 glutamate metabolic process. - CHEBI chemicals: pyridoxal 5′-phosphate CHEBI:18405; pyridoxine CHEBI:16709; L-lysine CHEBI:18019; GABA CHEBI:16865; pipecolic acid CHEBI:17964; α-aminoadipic acid CHEBI:37024 (verify all IDs with OAK).

Molecular profiling / omics: untargeted metabolomics has been the productive omics angle — recent work identified novel pyridoxine-independent diagnostic markers (6-hydroxy-2-aminocaproic acid [HACA] and a C₉H₁₁NO₄ isomer), plus 2-oxopropyl-P6C / 6-oxo-pipecolic acid as emerging biomarkers. No characteristic transcriptomic/proteomic/lipidomic disease signature is established beyond the lysine-pathway metabolite fingerprint. Functional genomics: the zebrafish CRISPR knockout (see §15) is the main perturbation model.

Sources: Mills 2006, Global metabolomics, PMC9784804, Biomarkers review, doi:10.3390/biom16040486.

7. Anatomical Structures Affected

  • Organ / system level: the central nervous system is the primary and essentially sole target (UBERON:0000955 brain; nervous system UBERON:0001016). The neonatal multisystem picture (feeding, respiratory, metabolic disturbance) is a functional/metabolic spillover rather than fixed organ pathology.
  • Regional/structural: corpus callosum (UBERON:0002336) — thin posterior segment (isthmus) is near-universal; ventricular system (ventriculomegaly), cisterna magna (mega cisterna magna), and scattered white-matter abnormalities, cortical dysplasia, and hydrocephalus in subsets.
  • Tissue / cell level: neurons, especially GABAergic neurons (CL:0000617); the defect is biochemical/global rather than a focal lesion.
  • Subcellular: lysine catabolism spans cytosol and mitochondrion (GO:0005739 mitochondrion; GO:0005829 cytosol); the PLP-dependent reactions affected are largely cytosolic.
  • Lateralization: structural changes (callosal thinning, ventriculomegaly) are typically bilateral/midline; seizures may be focal or generalized.

Sources: GeneReviews NBK1486, Coughlin 2023, PMC12360241.

8. Temporal Development

  • Onset: classically neonatal — seizures within the first hours to weeks of life, often with prolonged seizures and recurrent status epilepticus. A meaningful minority present late/atypical, with onset up to ~2–3 years (rarely into later childhood/adolescence). Fetal presentations (abnormal fetal movements, ventriculomegaly on prenatal ultrasound) are documented.
  • Onset pattern: acute/dramatic seizure onset on a background of a chronic, lifelong metabolic defect.
  • Course: chronic, lifelong — pyridoxine dependence is permanent; withdrawal reliably brings seizures back (a diagnostic feature historically, though rechallenge is now discouraged when genetic/biochemical confirmation is available). With treatment the course is stable with respect to seizures but the developmental disability is largely fixed/static rather than progressive-degenerative.
  • Breakthrough seizures: can occur with intercurrent illness, fasting, or medication lapses; myoclonic seizures and status epilepticus are risk factors for breakthroughs; folinic acid is added when pyridoxine responsiveness is incomplete.
  • Critical window (key actionable point): early treatment matters. Reported observation — a delay of up to ~4 days may not add harm, but delays >1 week associate with increased risk of learning difficulties and cerebral palsy; the substrate-reduction (triple) therapy also works best when started early.

Sources: GeneReviews NBK1486, Coughlin 2015, nationwide age-span study, ScienceDirect S0920121123000244.

9. Inheritance and Population

  • Inheritance: autosomal recessive (HP:0000007). Bind inheritance_term to HP:0000007 Autosomal recessive inheritance.
  • Penetrance: effectively complete in biallelic pathogenic-variant carriers; heterozygous carriers are unaffected.
  • Expressivity: variable — from severe classic neonatal encephalopathy to milder late-onset, correlating loosely with residual enzyme activity.
  • Genetic anticipation: not applicable (not a repeat-expansion disorder).
  • Germline mosaicism: not a described recurrence mechanism.
  • Founder effect / consanguinity: Dutch founder haplotype for E399Q (PMID:17721876); consanguinity elevates risk as for any AR condition.
  • Carrier frequency: used to derive incidence estimates (below).

Epidemiology: - Historical clinical-diagnosis incidence estimates vary widely: ~1:20,000 (a single German center), 1:396,000 (Netherlands), 1:783,000 (UK). - Carrier-frequency-based modeling gives ~1:64,352 live births — likely a better population estimate, since clinical case-finding under-ascertains atypical/late-onset cases. - Orphanet classes it as a rare disease (prevalence <1/1,000,000 to a few per million depending on region).

Suggested Prevalence records (dismech structured format): - population: Germany (single-center) · measure_type: BIRTH_PREVALENCE · rate ~5 per 100,000 (1:20,000) · notes: highest regional estimate. - population: Worldwide (carrier-frequency model) · measure_type: BIRTH_PREVALENCE · rate ~1.55 per 100,000 (1:64,352) · prevalence_class: BAND_1_9_PER_100000. - population: United Kingdom · measure_type: BIRTH_PREVALENCE · rate ~0.13 per 100,000 (1:783,000).

Demographics: no strong sex bias (AR disorder; M:F ≈ 1:1). Reported across many ethnic groups worldwide; specific variants show regional clustering (E399Q in European/Dutch populations). Age distribution is dominated by neonatal/infant diagnosis, with a long tail of later-recognized atypical cases.

Sources: GeneReviews NBK1486, Coughlin 2019, PMC6345606, Bennett/Salomons 2007.

10. Diagnostics

Biochemical (first-line, and the historical breakthrough): - Urinary/plasma/CSF α-AASA (α-aminoadipic semialdehyde) — the classic, robust diagnostic marker. Mills 2006 established that measurement of urinary α-AASA provides a simple diagnostic confirmation. - P6C (Δ¹-piperideine-6-carboxylate) — in equilibrium with α-AASA; sum of AASA+P6C tracked in therapy. - Pipecolic acid — elevated in plasma/CSF/urine, but less specific (rises in other conditions, e.g. peroxisomal disorders) and pyridoxine treatment lowers it, so it can normalize on treatment. - Emerging pyridoxine-independent markers: 6-hydroxy-2-aminocaproic acid (HACA), a C₉H₁₁NO₄ isomer, and 2-oxopropyl-P6C / 6-oxo-pipecolic acid — useful because they stay elevated even after treatment starts (helpful when a patient is already on B6).

Genetic confirmation (definitive): - ALDH7A1 sequencing (single-gene or via gene panel). Because rare exonic/whole-gene deletions are missed by sequencing, add deletion/duplication (CNV) analysis if only one variant is found. - WES/WGS increasingly first-line, especially for atypical/late presentations; rapid genome sequencing has diagnosed late-onset B6-dependent epilepsy. - Prenatal diagnosis feasible once familial variants are known (Mills 2006: gene analysis enables prenatal diagnosis).

Clinical / therapeutic test: - Pyridoxine trial: IV pyridoxine (with EEG and cardiorespiratory monitoring — apnea/hypotonia can follow the first dose) producing prompt clinical + electrographic seizure cessation. Historically a diagnostic pyridoxine-withdrawal rechallenge was used; now discouraged in favor of biochemical + genetic confirmation. - Folinic acid consideration when pyridoxine responsiveness is incomplete (given the FARS = PDE identity).

Imaging: MRI shows thin posterior corpus callosum (isthmus) (near-universal, demonstrable by geometric morphometry), plus ventriculomegaly, mega cisterna magna, white-matter changes, occasional cortical dysplasia/hydrocephalus. Imaging supports but does not confirm.

EEG: variable — burst-suppression, multifocal/generalized epileptiform discharges; the electrographic response to pyridoxine is itself informative.

Differential diagnosis — the other vitamin B6-dependent epilepsies (critical to distinguish):

Gene Disorder Distinguishing feature
PNPO Pyridox(am)ine 5′-phosphate oxidase deficiency Often responds to PLP rather than pyridoxine; different biomarker profile
PLPBP (formerly PROSC) PLP homeostasis protein defect B6-dependent, normal α-AASA; distinct from PNPO despite overlap
ALPL Hypophosphatasia Low alkaline phosphatase; pyridoxine-responsive seizures + skeletal disease
ALDH4A1 Hyperprolinemia type II Elevated proline/P5C; B6-responsive seizures

The unifying frame: "Vitamin B6-dependent epilepsies are caused by mutations in at least five different genes involved in B6 metabolism... The ALDH7A1, PNPO, ALPL, ALDH4A1, and more recently PLPBP genes have been implicated" (PLPBP review, PMC7932866). NEC caution for curation: because these disorders share the "vitamin B6-dependent epilepsy" label, deep-research tools are prone to conflating ALDH7A1 with PNPO/PLPBP — verify that every cited paper is specifically about ALDH7A1 before quoting.

Screening: not yet in most standard newborn-screening panels, though α-AASA is being evaluated as a newborn-screening analyte; cascade/carrier testing for relatives once a familial variant is known.

Sources: Mills 2006, Metabolomics biomarkers, PMC9784804, PLPBP review, PMC7932866, GeneReviews NBK1486.

11. Outcome / Prognosis

  • Survival / mortality: with prompt, sustained pyridoxine therapy, survival is generally good; the danger is undiagnosed/untreated disease, where refractory status epilepticus can be fatal. No robust disease-specific survival percentages, but early death is uncommon once treated.
  • Morbidity — the defining prognostic reality: ~75% have significant developmental delay / intellectual disability despite good seizure control (Coughlin 2015 [VERBATIM-VERIFIED]). Motor impairment, language delay, and behavioral/autistic features are common.
  • Prognostic factors: (1) time to diagnosis/treatment — delays >1 week worsen outcome; (2) phenotype/onset — late-onset patients tend to have better cognition; (3) genotype/residual activity; (4) use of adjunctive substrate-reduction therapy started early.
  • Disease course: seizures become controllable and stable; the neurodevelopmental deficit is largely static (present from early on rather than degenerative). Breakthrough seizures occur with illness/fasting/nonadherence.
  • Recovery potential: seizures — excellent with B6; cognition — limited once established, which is exactly why the field has pushed toward earlier and substrate-reducing treatment.

Sources: Coughlin 2015, Coughlin 2023 review, PMC12360241, GeneReviews NBK1486.

12. Treatment

Foundation — pyridoxine (vitamin B6) supplementation, lifelong. - Restores the depleted PLP pool by mass action, rescuing GAD/GABA synthesis. Immediate seizure control is the hallmark. - Dosing individualized; caution at first IV dose (apnea/hypotonia risk → monitor). Excess pyridoxine risks sensory neuropathy, so dose is balanced. - CHEBI:16709 pyridoxine. Suggested MAXO: dietary/vitamin supplementation (MAXO:0000088 dietary intervention as the closest broad term) + pharmacotherapy (NCIT:C15986) with therapeutic_agent pyridoxine (CHEBI:16709). Verify best MAXO term with OAK.

Substrate-reduction "triple therapy" (pyridoxine + dietary lysine restriction + L-arginine supplementation) — targets the neurotoxic-metabolite arm that B6 alone doesn't fix:

triple therapy "further reduced toxic metabolites, and in some subjects appeared to improve neurodevelopmental outcome" and "early diagnosis and treatment with this new triple therapy may ameliorate the cognitive impairment in PDE." [VERBATIM-VERIFIED, PMID:26026794] - Lysine restriction = less substrate feeding the blocked pathway (MAXO:0000088 dietary intervention; CHEBI:18019 L-lysine). - L-arginine competes with lysine for the brain/mitochondrial transporter, lowering intracerebral lysine (CHEBI:16467 L-arginine). - Best results when started early.

Adjunct — folinic acid for incomplete pyridoxine responsiveness or breakthrough seizures (folinic-acid-responsive seizures are the same ALDH7A1 disorder; CHEBI:63606 folinic acid).

Anti-seizure medications: generally insufficient alone (that refractoriness is diagnostic), but sometimes used adjunctively during stabilization.

Pharmacogenomics: not a major factor — treatment is genotype-agnostic vitamin/dietary therapy rather than metabolized small-molecule drugs.

Advanced / experimental therapeutics: no approved gene therapy, cell therapy, or RNA therapy for PDE as of this review; substrate-reduction optimization and earlier diagnosis (newborn screening) are the active translational frontiers. Check ClinicalTrials.gov for current lysine-restriction / arginine and biomarker studies (no landmark NCT to cite as established standard here).

Supportive/rehabilitative: developmental services, PT/OT/speech therapy, special education for the ID component.

Sources: Coughlin 2015, Effect of lysine restriction + arginine, PMID:27324284, Consensus recommendations, ScienceDirect S1096719211001661, GeneReviews NBK1486.

13. Prevention

  • Primary prevention: not preventable at the individual level (genetic). Population approach = carrier screening / genetic counseling for at-risk families, prenatal diagnosis, and preimplantation genetic testing where familial variants are known.
  • Secondary prevention (early detection): the biggest opportunity — earlier diagnosis (biomarker + genetic) to start treatment before neurodevelopmental damage accrues. Newborn-screening evaluation of α-AASA is an active area precisely because early treatment improves outcomes.
  • Tertiary prevention (limiting complications in diagnosed patients): sustained pyridoxine adherence, triple therapy to reduce neurotoxic metabolites, sick-day management to prevent breakthrough seizures during fasting/illness, and developmental support.
  • Counseling: AR recurrence risk 25% per pregnancy for carrier couples → genetic counseling is standard.

Sources: GeneReviews NBK1486, Coughlin 2015.

14. Other Species / Natural Disease

  • Taxonomy: human disease (NCBITaxon:9606). ALDH7A1 is highly evolutionarily conserved — hence the name antiquitin ("ancient" gene).
  • Orthologs: conserved orthologs in mouse (Aldh7a1), zebrafish (aldh7a1), and beyond; the deep conservation of the lysine-degradation/aldehyde-dehydrogenase function is what makes cross-species modeling informative.
  • Naturally occurring animal disease: no well-established spontaneous companion-animal or wildlife equivalent of PDE is described (check OMIA for any veterinary antiquitin phenotype; none prominent).
  • Comparative biology: conservation of the mechanism (lysine catabolism → α-AASA/P6C → PLP inactivation) is what allows the zebrafish model to faithfully reproduce the human biochemistry.

Sources: Zebrafish model, PMC5714462, OMIM *107323.

15. Model Organisms

Zebrafish (the flagship model): aldh7a1⁻/⁻ knockout generated with CRISPR-Cas9 — the first genetic PDE animal model. It recapitulates the human disease remarkably well: - Seizure behavior: spontaneous rapid locomotion and circling swim, earliest ~8 dpf; EEG shows large-amplitude spike discharges vs wild type. - Pharmacology matches humans: "the seizures show an almost immediate sensitivity to pyridoxine and pyridoxal 5′-phosphate, with a resulting extension of the life span" (paraphrased from the model paper). - Biochemistry matches humans: "Impaired lysine degradation with accumulation of PDE biomarkers, B6 deficiency, and low γ-aminobutyric acid levels were observed in the aldh7a1−/− larvae" — directly ties the metabolite build-up to the low-GABA/seizure mechanism. - Evidence source for these = MODEL_ORGANISM (in vivo animal).

Two independent zebrafish reports: Pena et al., Genetics 2017 (doi:10.1534/genetics.117.300137) and Zabinyakov et al., PLOS One 2017 (PMID:29053735).

Mouse: no widely characterized Aldh7a1 knockout mouse recapitulating the full PDE phenotype was found in this search (a notable model gap — worth flagging as a KNOWLEDGE_GAP or HUMAN_MODEL_MISMATCH candidate in the entry).

In vitro / cellular / computational: recombinant antiquitin biochemistry and structural/computational analysis of missense variants (e.g., ScienceDirect S000927972400139X) support loss-of-function interpretation; iPSC/organoid PDE models are not yet established.

Applications: the zebrafish model is used to study seizure mechanism, screen B6-vitamer and substrate-reduction responses, and validate biomarkers.

Sources: Zebrafish, Genetics 2017, Zabinyakov PLOS One, PMID:29053735, Zebrafish model PMC5714462.

Curation cheat-sheet (for the dismech entry)

  • Module conformance: epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance — PDE is a clean downstream conformer (PLP depletion → GAD failure → low GABA → E/I imbalance → seizures). Consider also flagging the lysine-catabolism/metabolic-block chain (it's an intoxication-flavored inborn error, though the acute-decompensation module fits less cleanly than for the classic organic acidemias).
  • Highest-confidence PMIDs with verified verbatim quotes: 16491085 (Mills 2006, mechanism/Knoevenagel), 20554659 (Mills 2010, phenotype spectrum + enzyme reaction), 26026794 (Coughlin 2015, 75% ID + triple therapy).
  • Leads to fetch-and-verify before quoting: 17721876 (founder), 29053735 (zebrafish), 27324284 (lysine/arginine), 19128019 (Gallagher, FARS=PDE — [VERIFY PMID]), plus the biomarker/metabolomics papers.
  • Watch for NEC: confirm every source is ALDH7A1-specific, not PNPO/PLPBP/ALPL — they all wear the "vitamin B6-dependent epilepsy" jacket.

Sources (primary set): - Mills PB et al., Nat Med 2006 — PMID:16491085 - Mills PB et al., Brain 2010 — PMID:20554659 - Coughlin CR et al., Mol Genet Metab 2015 — PMID:26026794 - GeneReviews: Pyridoxine-Dependent Epilepsy – ALDH7A1, NBK1486 - OMIM #266100 (EPEO4) · OMIM *107323 (ALDH7A1) - Coughlin genotypic spectrum 2019, PMC6345606 - Bennett/Salomons founder effect 2007 — PMID:17721876 - Global metabolomics biomarkers, PMC9784804 - PLPBP/B6-epilepsy differential review, PMC7932866 - Zabinyakov zebrafish model — PMID:29053735 · Zebrafish PMC5714462 - Coughlin current-perspectives review 2023, PMC12360241 - MedlinePlus Genetics: PDE

That's the whole map, Harry. The one-sentence version if you're skimming: a broken lysine-cleanup enzyme (antiquitin/ALDH7A1) lets a metabolite build up that chemically strangles vitamin B6, the brain runs out of the cofactor it needs to make its "calm down" signal, and you get B6-rescuable seizures — but the metabolite is also quietly toxic, which is why ~75% of kids still have intellectual disability even when the seizures are under control, and why the field moved to triple therapy. Just remember every PMID here is a lead until just fetch-reference confirms the snippet — I verified three of them verbatim, the rest need the usual cache-and-check pass before they land in the entry.